<DOC>
	<DOCNO>NCT00556270</DOCNO>
	<brief_summary>The aim study evaluate efficacy safety matrifen patient severe chronic pain sufficiently treat opioid analgesic ( WHO class 3 ) .</brief_summary>
	<brief_title>Efficacy Matrifen Patients Older Than 18 Years With Severe , Chronic Pain</brief_title>
	<detailed_description />
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>Main inclusion criterion : Patients severe , chronic pain Main exclusion criterion : Hypersensitivity fentanyl Coadministration monoaminooxidaseinhibitors Pregnancy Respiratory depression Chronic obstructive pulmonary disease ( COPD ) Drug abuse Impairment CNS function Other criterion define Summary Product Characteristics ( Fachinformation Chapter 4.3 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>pain</keyword>
	<keyword>fentanyl</keyword>
	<keyword>transdermal patch</keyword>
</DOC>